This outcome supports the consideration of the Liwen procedure as an effective therapeutic strategy for complex obstructive ALPK3-related HCM, but the 6-month follow-up is a recognized limitation in evaluating long-term outcomes for this potentially progressive cardiomyopathy. Here, ALPK3 is linked to cardiomyopathy.